Sensus Healthcare Reports the Death of Director Bill McCall
Passing of Bill McCall: Sensus Healthcare announces the passing of longtime friend and Director William "Bill" McCall, who played a crucial role in the company's development since 2009 and served on the Board since 2015.
Legacy and Contributions: Bill McCall was recognized for his financial acumen and leadership, significantly contributing to Sensus Healthcare's mission to provide patient-centric therapies, and was remembered as a trusted advisor and loyal friend.
Professional Background: McCall had a distinguished career in financial advisory and portfolio management, holding leadership positions at various firms and serving on multiple boards, including Cherokee Farm Partners.
Charitable Endeavors: Beyond his professional achievements, McCall was known for his charitable work, supporting educational and community organizations throughout Tennessee, leaving a lasting impact on both Sensus Healthcare and the community.
Trade with 70% Backtested Accuracy
Analyst Views on SRTS
About SRTS
About the author
New Financing Program Enhances Dermatology Equipment Acquisition
- Financing Program Launch: Sensus Healthcare has introduced a new financing service aimed at simplifying the acquisition process for dermatology practices seeking to purchase its superficial radiotherapy systems, thereby enhancing customer purchasing intent and market penetration.
- Conversion Rate Improvement: The new program is expected to improve the conversion rate of potential customers by reducing administrative and financing barriers, lowering the breakeven point to just one patient per month, which significantly alleviates the economic pressure of equipment procurement.
- Complementing Commercial Strategy: This financing service not only supports purchasing decisions for independent medical practices and corporate accounts but also strengthens relationships with physicians by providing financial visibility and reimbursement certainty, further solidifying Sensus' market position.
- Market Demand Response: With the new CPT codes providing approximately a 300% increase in per-fraction delivery codes for non-melanoma skin cancer treatment, Sensus' financing program will effectively support customer purchasing decisions in the new reimbursement environment, driving the company's growth in a rapidly evolving healthcare market.
Sensus Healthcare Reports Q4 2025 Earnings with Positive Outlook
- New Coding Opportunities: Sensus Healthcare received exclusive CPT codes from CMS, ensuring clear reimbursement for non-melanoma skin cancer treatments, which after 16 years of effort provides the company with a fresh start and enhances confidence in non-invasive alternatives for physicians and patients.
- Improved Financial Performance: Q4 2025 revenues reached $4.9 million, up from $3.1 million in Q4 2024, despite a net loss of $3.2 million; however, the company ended the year with $22.1 million in cash, indicating strong financial health.
- International Market Expansion: Six systems were shipped to countries including China in Q4, positively impacting margins from international sales, highlighting the company's growth potential in global markets, particularly in the Asia-Pacific region.
- Optimistic Future Outlook: Management expects Q1 2026 system shipments to exceed Q4 levels, even without contributions from its largest customer, with a goal of achieving full-year profitability, reflecting confidence in market demand.
Sensus Healthcare SRTS Q4 2025 Earnings Transcript
Sensus Healthcare to Announce Q4 Earnings on February 12
- Earnings Announcement: Sensus Healthcare (SRTS) is set to release its Q4 earnings on February 12 after market close, with a consensus EPS estimate of -$0.06, reflecting a significant year-over-year decline of 166.7%, indicating substantial profitability challenges for the company.
- Revenue Decline: The anticipated revenue for Q4 is $8.35 million, representing a 36.3% year-over-year decrease, which highlights potential challenges the company faces in a competitive market, further impacting its financial health.
- Earnings Performance Volatility: Over the past year, SRTS has only beaten EPS estimates 50% of the time, with a similar 50% success rate for revenue estimates, showcasing the uncertainty surrounding the company's performance that may affect investor confidence.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates and two downward revisions, while revenue estimates have seen three downward adjustments, indicating a pessimistic outlook from the market regarding the company's future performance.
Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections
Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.
Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.
Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.
Sensus Healthcare Recognized as One of TIME's Growth Leaders in America for 2026
Recognition of Sensus Healthcare: Sensus Healthcare has been named No. 72 on TIME's list of America's Growth Leaders of 2026, highlighting its revenue growth, financial stability, and stock performance over the past five years.
Focus on Non-Invasive Treatments: The company specializes in non-invasive treatments for skin conditions, particularly non-melanoma skin cancer and keloids, utilizing its superficial radiation therapy (SRT and IG-SRT) technology.
CEO's Statement: Joe Sardano, CEO of Sensus Healthcare, emphasized the importance of customer service and patient outcomes in achieving this recognition, crediting the support from physicians and patients over the past 15 years.
Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, indicating that actual results may differ from expectations due to various factors affecting the business and industry.
New Financing Program Enhances Dermatology Equipment Acquisition
- Financing Program Launch: Sensus Healthcare has introduced a new financing service aimed at simplifying the acquisition process for dermatology practices seeking to purchase its superficial radiotherapy systems, thereby enhancing customer purchasing intent and market penetration.
- Conversion Rate Improvement: The new program is expected to improve the conversion rate of potential customers by reducing administrative and financing barriers, lowering the breakeven point to just one patient per month, which significantly alleviates the economic pressure of equipment procurement.
- Complementing Commercial Strategy: This financing service not only supports purchasing decisions for independent medical practices and corporate accounts but also strengthens relationships with physicians by providing financial visibility and reimbursement certainty, further solidifying Sensus' market position.
- Market Demand Response: With the new CPT codes providing approximately a 300% increase in per-fraction delivery codes for non-melanoma skin cancer treatment, Sensus' financing program will effectively support customer purchasing decisions in the new reimbursement environment, driving the company's growth in a rapidly evolving healthcare market.
Sensus Healthcare Reports Q4 2025 Earnings with Positive Outlook
- New Coding Opportunities: Sensus Healthcare received exclusive CPT codes from CMS, ensuring clear reimbursement for non-melanoma skin cancer treatments, which after 16 years of effort provides the company with a fresh start and enhances confidence in non-invasive alternatives for physicians and patients.
- Improved Financial Performance: Q4 2025 revenues reached $4.9 million, up from $3.1 million in Q4 2024, despite a net loss of $3.2 million; however, the company ended the year with $22.1 million in cash, indicating strong financial health.
- International Market Expansion: Six systems were shipped to countries including China in Q4, positively impacting margins from international sales, highlighting the company's growth potential in global markets, particularly in the Asia-Pacific region.
- Optimistic Future Outlook: Management expects Q1 2026 system shipments to exceed Q4 levels, even without contributions from its largest customer, with a goal of achieving full-year profitability, reflecting confidence in market demand.
Sensus Healthcare SRTS Q4 2025 Earnings Transcript
Sensus Healthcare to Announce Q4 Earnings on February 12
- Earnings Announcement: Sensus Healthcare (SRTS) is set to release its Q4 earnings on February 12 after market close, with a consensus EPS estimate of -$0.06, reflecting a significant year-over-year decline of 166.7%, indicating substantial profitability challenges for the company.
- Revenue Decline: The anticipated revenue for Q4 is $8.35 million, representing a 36.3% year-over-year decrease, which highlights potential challenges the company faces in a competitive market, further impacting its financial health.
- Earnings Performance Volatility: Over the past year, SRTS has only beaten EPS estimates 50% of the time, with a similar 50% success rate for revenue estimates, showcasing the uncertainty surrounding the company's performance that may affect investor confidence.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates and two downward revisions, while revenue estimates have seen three downward adjustments, indicating a pessimistic outlook from the market regarding the company's future performance.
Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections
Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.
Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.
Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.
Sensus Healthcare Recognized as One of TIME's Growth Leaders in America for 2026
Recognition of Sensus Healthcare: Sensus Healthcare has been named No. 72 on TIME's list of America's Growth Leaders of 2026, highlighting its revenue growth, financial stability, and stock performance over the past five years.
Focus on Non-Invasive Treatments: The company specializes in non-invasive treatments for skin conditions, particularly non-melanoma skin cancer and keloids, utilizing its superficial radiation therapy (SRT and IG-SRT) technology.
CEO's Statement: Joe Sardano, CEO of Sensus Healthcare, emphasized the importance of customer service and patient outcomes in achieving this recognition, crediting the support from physicians and patients over the past 15 years.
Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, indicating that actual results may differ from expectations due to various factors affecting the business and industry.
